Miranda Jarrett Wallace, PhD
Associate Member
|
| Research Program:
Cancer Therapeutics
Faculty Rank:
Assistant Professor
Campus:
University of Arkansas for Medical Sciences
College:
College of Medicine
Department:
Microbiology & Immunology
|
Cancer Research Interest
- Disease Site Focus: GI
- Research Focus Area: Treatment
- Type of Research: Translational
- Research Keywords: Engineered probiotic, Colorectal cancer, Gastrointestinal tract, Therapeutic delivery
- Research Interest Statement: My laboratory is interested in harnessing microbes to both understand and overcome clinically significant disease arising in the gastrointestinal (GI) tract including colorectal cancer (CRC) and diarrheal disease. I have developed an orally delivered, engineered probiotic system capable of secreting protein-based therapeutics which demonstrated preclinical efficacy in producing immune checkpoint inhibitor proteins reducing intestinal tumor burdens in APCmin mice, as well as treatment of SARS-CoV-2 infection in the mouse GI tract. For my independent research career, I am developing a pipeline for therapeutic design and incorporation of bacterial toxin-neutralizing therapeutics into the engineered probiotic system. A developing cancer research project in my laboratory is using probiotics to neutralize Bacteroides fragilis toxin (BFT) which is produced by enterotoxigenic B. fragilis (ETBF). GI ETBF colonization is associated with CRC across multiple human cohort studies, and the molecular mechanism of BFT-mediated carcinogenic effects in the GI epithelium has been recently reported. Recent results in my lab demonstrate that these probiotics can produce BFT-binding nanobodies, and future efforts will determine the therapeutic efficacy of engineered probiotics against BFT-mediated pro-carcinogenic effects in tissue culture, organoid, and mouse models of colorectal cancer. This will set the foundation for establishing a therapeutic pipeline enabling incorporation of a wide array of protein-based therapeutics against emerging cancer-relevant targets in the engineered probiotic system.
Contact Information
- Email Address: MWallace5@uams.edu
- Profiles Research Networking Software: View Profile
Recent Publications
- Wallace MJ, Kratschmer C, Brazil B, [et al.]. A combinatorial construct library enables an expanded expression range of secreted therapeutic proteins by probiotic yeast. Trends in biotechnology. 2026. PMID: 42728171.
- Snoke HE, Reeve SM, Dharuman S, [et al., including Wallace MJ]. Development of Pyrimido Pyridazine Analogs through Increased Whole Cell Target Engagement of the Dihydropteroate Synthase Pterin Binding Site in Gram-Negative Bacteria. ACS infectious diseases. 2025 11(11):3237-3250. PMID: 41116192. PMCID: PMC12624742.
- Rebeck ON, Wallace MJ, Prusa J, [et al.]. A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden. Cell chemical biology. 2025 32(1):98-110.e7. PMID: 39571582. PMCID: PMC11741927.
- Fishbein SRS, DeVeaux AL, Khanna S, [et al., including Wallace MJ]. Commensal-pathogen dynamics structure disease outcomes during Clostridioides difficile colonization. Cell host & microbe. 2025 33(1):30-41.e6. PMID: 39731916. PMCID: PMC11717617.
- Jean S, Wallace MJ, Dantas G, Burnham CD. Time for Some Group Therapy: Update on Identification, Antimicrobial Resistance, Taxonomy, and Clinical Significance of the Bacteroides fragilis Group. Journal of clinical microbiology. 2022 60(9):e0236120. PMID: 35700139. PMCID: PMC9491163.
- Dharuman S, Wallace MJ, Reeve SM, [et al.]. Synthesis and Structure-Activity Relationship of Thioacetamide-Triazoles against Escherichia coli. Molecules (Basel, Switzerland). 2022 27(5). PMID: 35268619. PMCID: PMC8911640.
- Wallace MJ, Jean S, Wallace MA, [et al.]. Comparative Genomics of Bacteroides fragilis Group Isolates Reveals Species-Dependent Resistance Mechanisms and Validates Clinical Tools for Resistance Prediction. mBio. 2022 13(1):e0360321. PMID: 35038926. PMCID: PMC8764542.
- Fernando DM, Gee CT, Griffith EC, [et al., including Wallace MJ]. Biophysical analysis of the Mycobacteria tuberculosis peptide binding protein DppA reveals a stringent peptide binding pocket. Tuberculosis (Edinburgh, Scotland). 2022 132:102157. PMID: 34894561. PMCID: PMC8818035.
- Wang GC, Wallace MJ, Krishnan G, [et al.]. Spontaneous Bacterial Peritonitis Caused by Bordetella hinzii. Emerging infectious diseases. 2021 27(11):2966-2968. PMID: 34463239. PMCID: PMC8545000.
- Lang Y, Shah NR, Tao X, [et al., including Wallace MJ]. Combating Multidrug-Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling. Clinical pharmacology and therapeutics. 2021 109(4):1000-1020. PMID: 33576025. PMCID: PMC10662281.